Prolight Diagnostics AB - Company Research Report

Company Overview

Name

Prolight Diagnostics AB

Mission

Prolight Diagnostics AB aims to develop the foremost Point-Of-Care (POC) systems on the market for rapid and accurate diagnosis of acute conditions, specifically through innovations in patient-near analysis (PNA) systems.

Founding Details

• Founded: 1999

• Founder: Masoud Khayyami

Key People

• Ulf Bladin: CEO and Board Member. Holds a medicine candidate degree from Karolinska Institutet and a MSc from Handelshögskolan i Stockholm.

• Henrik Ljung: CFO. He is a business economist from Lund University.

• Karl Bullen: COO. Holds an engineering degree from the University of Greenwich.

• Aileen McGettrick: CSO. Holds a doctorate in biochemistry and genetics from Oxford University.

• Steve Ross: CTO. Holds a Ph.D. in synthetic chemistry from Edinburgh University.

• Paul Monaghan: Head of Engineering with a Ph.D. in microfluidic lab-on-a-chip devices from Imperial College, London.

• Sarah Campbell: Head of Product Development, MSc from Cranfield University.

• Andrew Goodenough: Head of QA/RA, studied engineering at Open University.

Headquarters

Lund, Sweden

Number of Employees

No information is available.

Revenue

No information is available.

Known For

Prolight is known for its innovative development of Point-Of-Care (POC) diagnostic systems, which allow for rapid, patient-near testing in various clinical settings.

Products

Overview

Prolight, together with its subsidiary Psyros Diagnostics Ltd, develops patient-near analysis (PNA) systems, also known as Point-Of-Care (POC) systems. These systems are portable and use disposable test cartridges for in vitro diagnostic tests from a drop of blood.

Key Products

1. Psyros™

• Description: A groundbreaking digital POC technology that counts individual molecules from a single drop of blood.

• Key Features:

• Portable and simple to operate.

• Detects biomarkers at extremely low concentrations.

• Offers performance, sensitivity, and precision akin to hospital laboratories.

• Provides results in under 10 minutes.

• Requires only a drop of blood.

• Multiplexing capability to test multiple biomarkers simultaneously.

• Low production costs translating to competitive pricing.

2. MicroFlex

• Description: Developed in collaboration with The Technology Partnership (TTP), combining ELISA technology in microformat with Flex Membrane technology.

• Key Features:

• Capable of ELISA tests with small, easy-to-use disposable test cards.

• Supports distributed diagnostic testing suitable for POC environments.

• Pre-prepared with necessary reagents for measurement directly from standard vacuum tubes.

• User-friendly workflow well-suited for POC applications.

Recent Developments

New Developments

• In 2022, Prolight signed a commercialization agreement for its MicroFlex POC platform with The Technology Partnership (TTP).

Product Launches

No new product launches are identified in the provided data.

New Features

The unique Psyros™ platform continues to hold potential for enhancements in molecule counting and low-level concentration detection.

Partnerships

• Integrated Technologies Limited (ITL): Developing instrumentations for Prolight’s Psyros™ system.

• MDx CRO: Leading the clinical performance study for Psyros™ troponin test validation.

• Flex Medical Solutions: Contract manufacturing partner for Psyros™ disposable test cards.

• Fleet Bioprocessing Ltd: Provides contract research and manufacturing services.

• The Technology Partnership (TTP): Collaborated with Prolight for the MicroFlex system development.

Other Partnerships

• Gooch & Housego PLC: Access to extensive expertise and resources due to ITL’s acquisition in 2018.

Conclusion

The report assembles key highlights of Prolight Diagnostics AB, a pioneering company in Point-Of-Care diagnostics, with substantial innovations in its Psyros™ and MicroFlex systems. With a robust framework supported by strategic partnerships and cutting-edge technology, Prolight aims to address unmet clinical needs with precision and speed in patient-near diagnostic solutions while targeting crucial areas like cardiac biomarker testing.